Add Formweb to your mobile device
Search results for:
epoetin alfa
epoetin alfa
Brand names: Epogen, Procrit, Retacrit
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, INJECTABLE | 10,000 units/mL preservative-free; 40,000 units/mL preservative-free; 2000 units/mL preservative-free; 3000 units/mL preservative-free; 4000 units/mL preservative-free; 20000 units/mL; epbx 10,000 units/mL preservative-free; epbx 20,000 units/mL; epbx 40,000 units/mL preservative-free; epbx 2000 units/mL preservative-free; epbx 3000 units/mL preservative-free; epbx 4000 units/mL preservative-free |
Last updated: May. 1, 2024
- Black Box Warning: Risk of mortality, tumor progression, cardiac events
- REMS: ESA APPRISE REMS eliminated April 2017
- Therapeutic Interchange: Biosimilar and Reference Products Conversion List for Adults
- Do Not Tube-LALK
- Do Not Tube-LACH
- Restricted: Procrit is restricted to outpatient only.
Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note: “Therapeutic Interchange” should be placed in the order comments)
Biosimilar and Reference Products Interchange List for Adults
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
Retacrit (epoetin alfa-epbx)
Biosimilar
Formulary
(preferred)
Use Retacrit
Use Retacrit unless third party payer requires other epoetin product
Procrit (epoetin alfa)
Reference
Formulary, restricted to OP
(not preferred)
Interchange to Retacrit
Interchange to Retacrit unless third party payer requires other epoetin product. If Epogen is required, NFT is needed.
Epogen (epoetin alfa)
Reference
Non-formulary